Prevalence of HIV-1 drug resistance in treated patients with viral load &gt;50&nbsp;copies/mL: a 2014 French nationwide study

Assoumou, L; Charpentier, C; Recordon-Pinson, P; Grudé, M; Pallier, C; Morand-Joubert, L; Fafi-Kremer, S; Krivine, A; Montes, B; Ferré, V; Bouvier-Alias, M; Plantier, J-C; Izopet, J; Trabaud, M-A; Yerly Ferrillo, Sabine; Dufayard, J; Alloui, C; Courdavault, L; Le Guillou-Guillemette, H; Maillard, Anne; Amiel, C; Vabret, A; Roussel, C; Vallet, Simon-Ulysse; Guinard, J; Mirand, A; Beby-Defaux, A; Barin, F; Allardet-Servent, A; Ait-Namane, R; Wirden, M; Delaugerre, C; Calvez, V; Chaix, M-L; Descamps, D; Reigadas, S

doi:10.1093/jac/dkx042

Scientific article

English

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

Published inJournal of Antimicrobial Chemotherapy, vol. 72, no. 6, p. 1769-1773

Publication date2017

Abstract

Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance.

Affiliation Not a UNIGE publication

Citation (ISO format)

ASSOUMOU, L et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. In: Journal of Antimicrobial Chemotherapy, 2017, vol. 72, n° 6, p. 1769–1773. doi: 10.1093/jac/dkx042

Article (Published version)

Identifiers

PID : unige:99803
DOI : 10.1093/jac/dkx042
PMID : 28333232

ISSN of the journal0305-7453

419views

2downloads

Creation10/30/2017 11:08:00 AM

First validation10/30/2017 11:08:00 AM

Update time03/15/2023 2:30:19 AM

Status update03/15/2023 2:30:17 AM

Last indexation01/17/2024 1:37:28 AM

Archive ouverte UNIGE

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance.

Technical informations